600276 恒瑞医药
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)8.55914.73910.99110.72813.831
总资产报酬率 ROA (%)7.87413.4939.9889.57012.245
投入资产回报率 ROIC (%)8.49614.57210.64810.33213.551

边际利润分析
销售毛利率 (%)86.58186.24984.55283.61285.556
营业利润率 (%)32.73226.76721.51619.32718.007
息税前利润/营业总收入 (%)30.51723.57418.35616.44015.936
净利润/营业总收入 (%)28.26422.64518.74617.93217.309

收益指标分析
经营活动净收益/利润总额(%)96.24097.30798.68388.90592.080
价值变动净收益/利润总额(%)1.7641.575-2.30211.6895.590
营业外收支净额/利润总额(%)-2.137-4.476-5.202-3.615-4.445

偿债能力分析
流动比率 (X)13.4959.71912.2528.5008.875
速动比率 (X)12.7509.05411.3467.8278.168
资产负债率 (%)6.1438.0696.2849.3419.409
带息债务/全部投入资本 (%)-0.030-0.0540.9724.0481.586
股东权益/带息债务 (%)-334,099.590-184,059.23510,140.5082,350.5206,155.215
股东权益/负债合计 (%)1,513.1751,125.2271,470.724955.631947.456
利息保障倍数 (X)-19.955-11.518-8.756-7.428-12.216

营运能力分析
应收账款周转天数 (天)56.74565.02587.44489.03867.442
存货周转天数 (天)212.692221.301243.282250.552201.115